Drug Research
Drug Discovery & Development

Drug Discovery & Development News

View news from other Pharmaceutical sectors:
91-105 of 4728 results
Constellation Pharmaceuticals raises $100m financing to advance multiple clinical trials
Constellation Pharmaceuticals, a clinical-stage biopharmaceutical company developing tumor-targeted and immuno-oncology therapies, has raised a $100m financing.
Drug Research > Drug Discovery & Development > News
AstraZeneca licenses Ionis' NASH drug in $300m deal
By PBR Staff Writer
AstraZeneca has licensed a fatty liver disease treatment IONIS-AZ6-2.5-LRx (AZD2693) from Ionis Pharmaceuticals in a deal that could fetch up to $300m for the California firm in milestone payments.
Drug Research > Drug Discovery & Development > News
Novo Nordisk secures licence to EpiDestiny’s sickle cell disease program
Novo Nordisk has obtained an exclusive worldwide licence to EpiDestiny’s sickle cell disease (SCD) programme, EPI01.
Drug Research > Drug Discovery & Development > News
Novartis to acquire US gene therapy firm AveXis for $8.7bn
By PBR Staff Writer
Swiss drugmaker Novartis has agreed to acquire AveXis, a US-based clinical stage gene therapy company, for $8.7bn in an all-cash deal.
Drug Research > Drug Discovery & Development > News
Ferring Pharmaceuticals to buy US firm Rebiotix
By PBR Staff Writer
Switzerland-based Ferring Pharmaceuticals has agreed to acquire US clinical stage biotechnology firm Rebiotix for an undisclosed sum.
Drug Research > Drug Discovery & Development > News
Proteostasis’ triple combination program secures FDA fast track status for cystic fibrosis
Proteostasis Therapeutics has secured fast track designation from the US Food and Drug Administration (FDA) for its triple combination program to treat cystic fibrosis.
Drug Research > Drug Discovery & Development > News
Roche acquires Inception neuroscience program
Roche has acquired the Inception 5 program, which is focused on regenerative therapies for multiple sclerosis.
Drug Research > Drug Discovery & Development > News
Boehringer, OSE Immunotherapeutics sign $1.4bn immuno-oncology deal
By PBR Staff Writer
Boehringer Ingelheim has entered into an exclusive worldwide collaboration and license agreement with OSE Immunotherapeutics for the development of a new checkpoint inhibitor to treat solid tumors.
Drug Research > Drug Discovery & Development > News
Pfizer to hold 25% ownership stake in Allogene Therapeutics
Pfizer has signed an asset contribution agreement with Allogene Therapeutics for its Allogeneic CAR T immuno-oncology portfolio.
Drug Research > Drug Discovery & Development > News
Dr. Reddy’s, Promius Pharma file NDA with FDA for migraine candidate
By PBR Staff Writer
Dr. Reddy’s Laboratories and its subsidiary Promius Pharma have filed a new drug application (NDA) with the US Food and Drug Administration (USFDA) for migraine candidate DFN-02.
Drug Research > Drug Discovery & Development > News
MedImmune, Compugen sign immuno-oncology deal
By PBR Staff Writer
Compugen has signed an exclusive license agreement with AstraZeneca’s subsidiary MedImmune for the development of bi-specific and multi-specific immuno-oncology antibody products.
Drug Research > Drug Discovery & Development > News
Actinium Pharmaceuticals, Astellas collaborate on AWE platform technology
Actinium Pharmaceuticals has entered into a research and option agreement with Astellas Pharma to develop Actinium-225 Radio-Conjugates (ARCs) using its Actinium Warhead Enabling (AWE) platform technology.
Drug Research > Drug Discovery & Development > News
Bluebird, Celgene to co-develop anti-BCMA CAR T cell therapy for multiple myeloma
bluebird bio and Celgene have agreed to co-develop and co-promote bb2121, an investigational anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cell therapy for the potential treatment of relapsed/refractory multiple myeloma in the US.
Drug Research > Drug Discovery & Development > News
Takeda mulls bid for biopharmaceutical firm Shire
By PBR Staff Writer
Japanese drugmaker Takeda said it is considering a possible offer for the acquisition of Shire, Irish-headquartered global specialty biopharmaceutical company.
Drug Research > Drug Discovery & Development > News
Chinese biotech company Adagene raises $50m in new funding round
Adagene, an antibody discovery and development company, has raised $50m in Series C financing, led by Sequoia China, and backed by New World TMT, AVIC Trust, King Star Capital, Gopher Asset Management and other investors.
Drug Research > Drug Discovery & Development > News
91-105 of 4728 results